# EVX Ventures

EVX Ventures is a Venture Capital based in Singapore, Singapore.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Singapore, Singapore
- **Region:** Asia
- **Address:** Blk 5014 Ang Mo Kio Avenue 5, Techplace II, Singapore 569881
- **Founded:** 2015
- **Assets under management:** Undisclosed
- **Website:** www.evx.ventures
- **LinkedIn:** https://www.linkedin.com/company/evxventures

## Regulatory record

- **Reports private funds:** No

## About

EVX Ventures is a global investor focused on the life sciences and healthcare sectors. Based in key hubs like Singapore and Shanghai, it leverages extensive global networks to foster cross-border ecosystems and drive innovation. It is a life sciences venture builder headquartered in Singapore. Its mission is to invest in life sciences ventures and support their growth, creating lasting impact worldwide.

## Sectors

- Biotech
- Healthcare Services

## Offices

- Shanghai, China

## Questions

### Does EVX Ventures incubate its own companies, or does it invest in external founders?

EVX acts primarily as a company builder. It co-founds biotech startups directly with academic scientists, taking a founder-level role rather than acting as a passive early-stage investor. Portfolio companies like Carcell Biopharma and Carmine Therapeutics were created by EVX Ventures alongside professors from institutions such as MIT and Duke-NUS Medical School (per firm website).

### Which therapeutic platforms does EVX Ventures focus on?

The portfolio concentrates on three platform clusters: engineered red blood cells for immuno-modulation and non-viral gene delivery (Carcell, Carmine); gene therapy vectors and RNA medicines for genetic heart and liver diseases (Nuevocor, Lerna Biopharma); and novel immuno-oncology targets derived from aberrant splicing and T-cell activation mechanisms (PairX Bio, AltruBio, Hummingbird Bioscience).

### How does EVX Ventures source its deals?

Deal flow originates from deep collaborations with university laboratories, particularly Duke-NUS Medical School in Singapore and Prof. Harvey Lodish's research group at MIT. The firm builds companies around published science, often securing IP from those institutions and embedding the originating scientists as co-founders or scientific advisory board chairs.

### What investment stages does EVX Ventures target?

EVX targets the full preclinical-to-early-clinical continuum. It engages at the discovery stage, builds companies through target validation, and funds programs into Phase II clinical trials. Hummingbird Bioscience's pipeline is described as advancing through Phase II, while most other portfolio companies remain preclinical or Series A stage (per firm website).

### Is EVX Ventures structured as a corporate venture arm of a larger life-science parent?

There is no publicly disclosed corporate parent. EVX Ventures does describe itself as a 'global VC' and company builder operating independently. It does not list affiliation with Esco Lifesciences or any other pharmaceutical group, though its domain history and entity naming suggest a possible historical relationship that the firm itself does not confirm.

## Related profiles

- [EV Private Equity](https://altss.com/profile/ev-private-equity)
- [EWA Capital](https://altss.com/profile/ewa-capital)

---

Last updated: 2026-08-11T15:06:42.396Z

Canonical page: https://altss.com/profile/evx-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology